by 
The global epidermolysis bullosa market is experiencing significant growth owing to advancements in gene therapy. Epidermolysis bullosa is a rare inherited skin disease characterized by blistering of the skin and mucous membranes due to minor mechanical friction or trauma to the skin. Conventional treatments involving wound dressings, antibiotic treatment for infection of blisters, sterile environment, and topical steroids are being increasingly replaced by novel gene therapies that target the root cause of the disease. Gene therapy aims at replacing the defective gene that causes EB to be able to produce collagen protein properly.
The global Epidermolysis Bullosa market is estimated to be valued at US$ 3,429.30 Mn in 2024 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the epidermolysis bullosa market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair. These players are extensively involved in developing approved therapies and conducting clinical trials to validate novel treatments.
The key opportunities in the market include a large patient pool in need of effective treatments, increasing research funding for orphan diseases, and growing awareness about EB. There is also a strong pipeline of gene and cell-based therapies that are expected to receive approvals over the forecast period.
Advancements in gene transfer technologies such as viral and non-viral vectors are facilitating progress in gene therapy approaches for EB. Novel gene editing tools like CRISPR-Cas9 also hold promise for precisely correcting defective genes and developing curative therapies.
Market drivers
Rising prevalence of Epidermolysis Bullosa worldwide is a major driver of market growth. According to estimates, the disease affects over 500,000 people globally. Growing research into understanding the molecular basis of different EB subtypes is also supporting the development of targeted treatment approaches. Additionally, the orphan drug designation and incentives provided by regulatory authorities to drug developers are encouraging investments in EB drug development. This is expected to translate into new product approvals and market expansion over the coming years.
Current challenges in EB market
Epidermolysis bullosa (EB) is a rare genetic connective tissue disorder that causes easy blistering of the skin and mucous membranes. The disease has no definitive cure and presents challenges for both patients and healthcare professionals. Currently available treatment options offer only symptomatic relief and focus on wound care management. Developing widely effective and affordable treatment options remains a major challenge in the EB market due to the complexity of the disease and limited research.
SWOT Analysis
Strengths: Growing research activity and new drug approvals offer hope. Increased awareness about EB is supporting funding for research.
Weaknesses: Lack of comprehensive treatment options. High cost of current therapies limits access. Disease complexity hinders development of cure.
Opportunities: Cell and gene therapies have potential to alter natural disease course. Development of innovative delivery methods can improve therapies.
Threats: Long development cycles and high failure rates in rare disease research may deter investment. Limited patient populations pose commercialization challenges.
Geographical regions by value
North America currently accounts for the largest share of the global EB market due primarily to growing research activity, healthcare investments and presence of key market players in the region. Europe is the second largest market driven by supportive regulatory environment and increasing focus on orphan drugs.
Fastest growing region
Asia Pacific region is poised to witness the highest growth in the EB market during the forecast period owing to rising healthcare expenditures, increasing healthcare access and growing incidence of EB and other rare diseases in developing countries of the region. expanding collaborations between regional and global market players will further support market growth in Asia Pacific.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
